June 27, 2022

BioTissue Co-Founder Recognized as Pioneer in Amniotic Membrane Technology Research for Ocular Surface Regeneration

Game-changing research conducted under Dr. Scheffer C.G. Tseng is most cited laboratory investigation in the history of corneal research

Miami, June 27, 2022—BioTissue, Inc., an emerging biotechnology company and leader in harnessing human birth tissue to support regenerative healing for ocular surface disease, announced that research conducted by co-founder and Chief Technology Officer Scheffer C.G. Tseng, MD, PhD, has become the most cited laboratory investigation in the history of corneal research.

Dr. Tseng’s work in amniotic membrane regenerative medicine in ophthalmology and the interest it has drawn from the scientific community has led to it being cited in more than 1,300 publications. The impact of this groundbreaking research is recognized and celebrated by Kenneth R. Kenyon MD, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, in a recent issue of Cornea Journal of Cornea and External Disease.

Laboratory-based research conducted by Dr. Tseng and his associates at the University of Miami demonstrated the potential for amniotic membrane to support corneal surface restoration. His research has become globally recognized as having been the first of its kind to show how limbal stem cell transplantation with amniotic membrane can support ocular surface reconstruction for injuries such as chemical or thermal burns and ocular surface disease.

In the Cornea Journal article, Dr. Kenyon wrote that a paradigm shift in Dr. Tseng’s research occurred in 1995 when his novel experiments modeled limbal stem cell deficiency in rabbits by chemically debriding the corneal epithelium plus surgically excising the limbal annulus, thereby extirpating the all-important limbal stem cells. One month later, a total lamellar keratectomy was performed, and the secondarily injured eyes received either an overlay graft of human amnion or no coverage. In more than two thirds of these cases, the amnion grafted eyes resulted in restored clear corneas with intact epithelium while the non-grafted eyes developed profound conjunctivalization.

Dr. Tseng said, “It is an honor to be recognized by my colleague, Dr. Kenyon. My research associates and I have worked diligently for more than three decades to demonstrate the potential for amnionic membrane to support corneal surface restoration. The results of our investigative research are the foundation on which BioTissue has been built.”

Dr. Tseng added that BioTissue’s ocular work has also laid the foundation for the company’s amnion-based generative healing products in other medical applications such as orthopedics, wound care, and neurosurgery.

About BioTissue, Inc.
BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues biologics license applications for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 680,000 human implants with its products and published over 380 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at biotissue.com.

Media Contact
Heather Kowalczyk, APR
McDougall Communications for BioTissue
[email protected] or (585) 434-2148


Related Content